USP consults on updated standards for PET drugs
This article was originally published in SRA
Executive Summary
The US Pharmacopeial Convention has proposed revisions to its quality assurance standards for the production and compounding of positron emission tomography drugs used in nuclear medicine, radiology and diagnostic imaging1.